Treatment | DA | DOPAC | HVA | DOPAC + HVA/DA | ||
---|---|---|---|---|---|---|
pmol / mg protein ± S.E.M. | ||||||
Control | 464 ± 8 | 74 ± 2 | 50 ± 3 | 0.26 | ||
+NSD | 389 ± 10 | 11 ± 1* | 21 ± 1* | 0.08 | ||
+CLZ | 580 ± 48 | 194 ± 30 | 86 ± 4 | 0.48 | ||
+NSD + CLZ | 430 ± 10 | 12 ± 1* | 22 ± 3* | 0.08 | ||
l-DOPA | 550 ± 31 | 160 ± 2 | 108 ± 13 | 0.49 | ||
+NSD | 546 ± 23 | 11 ± 2* | 18 ± 1* | 0.05 | ||
+CLZ | 567 ± 39 | 432 ± 57 | 177 ± 13 | 1.07 | ||
+NSD + CLZ | 635 ± 54 | 22 ± 3* | 20 ± 2* | 0.07 |
↵* p < 0.05 compared with comparison group not receiving NSD 1015. n = 6 to 8.